Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekend mometasone maintenance for seborrheic dermatitis
ACTRN12625001406493Phase 4Recruiting
- Sponsor
- Khyber Teaching Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mometasone in seborrheic dermatitis (SD) (2 arms), sponsored by Khyber Teaching Hospital. Primary endpoint: Time to relapse of seborrheic dermatitis symptoms requiring rescue therapy. Started Sep 2025; status: recruiting.
02
Drugs
mometasone
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on ACTRN12625001406493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001406493.